This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Experts estimate that global paid subscribers to streaming music services will grow from 176 million in 2017 to 293 million by 2021.
KKR MS.PRE P MS.PRF MS.PRG GOOG MS.PRA SNEJF SSDIY GS AMZN MS.PRI SPOT MS.PRK AAPL JEF SNE MS
In a recent contribution, I introduced some doubts as to the possibility for LG Chem to convert Pilbara’s lithium concentrates into lithium carbonate or hydroxide in South Korea.
SSDIY PLS PILBF AGO ATLGF AGODY PKX
Battery production continues to climb as automakers bring new options to market; new energy vehicle sales figures continue to rise.
PILBF SSNLF ALB TYHOF LACDF 2333 NMKEF GALXF GCPEY ALTAF NMX OROCF EGT MLNLF EGTYF LAC PLS PCRFY GCPEF GWLLY SSDIY GXY 8015 PKXFF AJM STGYF
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.
LIT SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF VLKAY AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF NMKEF LKE MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF PLS MSB DJI SSDIY PDDTF NTTHF AVLIF ORE AVZ AJM
Lithium spot and contract price news - Lithium spot prices were stable, while 2018 LCE global contract prices are about 20% higher than 2017.
LIT ORL BCN PILBF LTHHF LAXXF MS.PRE MS.PRF LIACF MS.PRG AGY MS.PRA NMT AGO GM.WS.A GM.WS.B GM.WS.C PLLLY RDRUY AZZVF MS WML SQM MLNLF AIS.H KDR STLHF SYA AGODY WMLLF LNRDY LIXXF NGZ AMVMF VLKAF GXY LMMFF MS.PRI TAW LRS MNIKF MS.PRK ILHMF AMLM 8015 GM.WSB ALB DMNXF TYHOF MALRY BGS LACDF EEYMF KIMTY MIN NMKEF TKL ARYMF ILC LIX MGXMF LSSCF ALTAF DJIFF KIMTF NMX CRECF EMH PSC GM OROCF ERPNF LAC PLS HYUO BCN TWNAF QBC HYUD DJI RRSSF SSDIY PDDTF NTTHF AVLIF ATLGF HYUP MALRF ORE AVZ AJM BCRMF
21h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
23h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET